Market Place
Sourcing Support
Altamira Pharma Updates Business & Reveals 2025 Financial Results
31 Mar 2026 //
PHARMIWEB
Altamira Pharma Sets 2025 Annual Report Release Date
24 Mar 2026 //
PHARMIWEB
Altamira Therapeutics: Japanese Patent for Intranasal Betahistine
15 Jul 2025 //
ACCESSWIRE
Altamira Therapeutic to Host 2024 Financial Results on April 30
25 Apr 2025 //
GLOBENEWSWIRE
Altamira Expands Bentrio Agreement With Nuance Pharma
16 Sep 2024 //
GLOBENEWSWIRE
Altamira Therapeutics to Present at H.C. Wainwright Global Conference
03 Sep 2024 //
GLOBENEWSWIRE
Altamira Extends Bentrio Distribution To Sweden And Denmark With Pharma Nordic
23 Aug 2024 //
GLOBENEWSWIRE
Altamira Confirms Suitability For Athletes With No Prohibited Substances
16 Aug 2024 //
GLOBENEWSWIRE
Altamira Bentrio Social Amplification: Seasonal Allergy Positive Results
23 May 2024 //
GLOBENEWSWIRE
Altamira`s Bentrio Allergic Rhinitis Data Published
24 Apr 2024 //
GLOBENEWSWIRE
Altamira Therapeutics Provides Financial Update, Reports FY 2023 Results
10 Apr 2024 //
GLOBENEWSWIRE
Altamira Therapeutics to Host Full Year 2023 Financial Results
04 Apr 2024 //
GLOBENEWSWIRE
Altamira Regains Compliance with Nasdaq Minimum Bid Price Requirement
29 Dec 2023 //
GLOBENEWSWIRE
Altamira Therapeutics Provides Investor and Business Update
11 Dec 2023 //
GLOBENEWSWIRE
Altamira lays off 25% of staff weeks after allergy spray spinoff
11 Dec 2023 //
FIERCE BIOTECH
Altamira Therapeutics to Host Investor & Business Update Call on December 11th
05 Dec 2023 //
GLOBENEWSWIRE
Altamira Regains Compliance with Nasdaq Minimum Stockholders` Equity Requirement
29 Nov 2023 //
GLOBENEWSWIRE
Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business
17 Nov 2023 //
GLOBENEWSWIRE
Altamira Announces Patent Office Decision to Grant for Intranasal Betahistine
10 Nov 2023 //
GLOBENEWSWIRE
Altamira Reports Additional Significant Efficacy Outcomes from Bentrio Trial
14 Sep 2023 //
GLOBENEWSWIRE
Altamira Provides Business Update and First Half 2023 Financial Results
12 Sep 2023 //
GLOBENEWSWIRE
Altamira Therapeutics to Host First Half 2023 Financial Results
06 Sep 2023 //
GLOBENEWSWIRE
Altamira to Present at H.C. Wainwright 25th Annual Investment Conference
23 Aug 2023 //
GLOBENEWSWIRE
Altamira Announces Publication of Positive Results from Trial with Bentrio
17 Jul 2023 //
GLOBENEWSWIRE
Altamira Therapeutics Announces Pricing of $5.0 Million Public Offering
06 Jul 2023 //
ACCESSWIRE
Altamira Announces IND Clearance by FDA for AM-125 in Acute Vestibular Syndrome
15 Jun 2023 //
ACCESSWIRE
Altamira Therapeutics Reports Positive Top-Line Data from Bentrio Clinical Trial
24 May 2023 //
ACCESSWIRE
Altamira Therapeutics Provides Business Update, Reports FY 2022 FYR
16 May 2023 //
ACCESSWIRE
Altamira Therapeutics to Host Fiscal Year 2022 Financial Results
12 May 2023 //
ACCESSWIRE
Altamira Therapeutics CEO & Chairman to Present at Sidoti Micro-Cap
01 May 2023 //
ACESSWIRE
Altamira Announces Publication of Positive Results from PII Trial with AM-125
12 Apr 2023 //
ACCESSWIRE
Clinical Study Demonstrates Bentrio`s Superior Nasal Residence Time
03 Mar 2023 //
ACCESSWIRE
Altamira Therapeutics to Report Bentrio Clinical Data at Feb. 25 AAAAI
14 Feb 2023 //
ACCESSWIRE
Altamira to Present at Two Upcoming RNA Therapeutics Conferences in Q1 2023
07 Feb 2023 //
ACCESSWIRE
Altamira stakes for-sale sign again after asset deal crumbles
28 Jan 2023 //
FIERCE BIOTECH
Altamira Therapeutics Provides Business Update
27 Jan 2023 //
GLOBENEWSWIRE
Altamira Therapeutics Provides Update on Clinical Trials with Bentrio
24 Jan 2023 //
GLOBENEWSWIRE
Altamira Therapeutics Provides Year-End 2022 Business Update
19 Dec 2022 //
GLOBENEWSWIRE
Altamira Therapeutics Reaches Midpoint for Enrollment in Clinical Trial
02 Dec 2022 //
ACCESSWIRE
Altamira Announces Launch of Bentrio in Hong Kong by its Partner Nuance Pharma
30 Nov 2022 //
GLOBENEWSWIRE
Altamira Therapeutics Provides Business Update and First Half 2022 FYR
30 Nov 2022 //
GLOBENEWSWIRE
Vivo Data Demonstrates Altamira`s SemaPhore mRNA Delivery Platform
22 Nov 2022 //
ACCESSWIRE
Altamira to Participate at TIDES Europe Oligonucleotide and Peptide Therapeutics
10 Nov 2022 //
GLOBENEWSWIRE
Altamira Therapeutics Regains Listing Compliance with NASDAQ
09 Nov 2022 //
GLOBENEWSWIRE
Altamira Therapeutics Announces Reverse Stock Split
24 Oct 2022 //
GLOBENEWSWIRE
Buyer snaps up Altamira`s inner ear R&D amid strategy shift
21 Oct 2022 //
FIERCEBIOTECH
Altamira Therapeutics Announces Divestiture of Inner Ear Development Assets
21 Oct 2022 //
GLOBENEWSWIRE
Altamira Therapeutics to Participate at RNA Leaders USA Congress
13 Oct 2022 //
GLOBENEWSWIRE
Altamira Continue Bentrio Clinical Trial for Seasonal Allergic Rhinitis
03 Oct 2022 //
GLOBENEWSWIRE
Altamira Therapeutics Re-launches Bentrio in Europe for Allergic Rhinitis
27 Sep 2022 //
GLOBENEWSWIRE
Altamira Therapeutics Completes Enrollment for COVAMID Trial with Bentrio
13 Sep 2022 //
GLOBENEWSWIRE
Altamira Therapeutics to Participate in the 4th Annual RAS-Targeted Drug Devp
08 Sep 2022 //
GLOBENEWSWIRE
Altamira Tx’s CEO Interviewed by Proactive Investors to Discuss its Pipeline
03 Aug 2022 //
GLOBENEWSWIRE
Altamira Therapeutics Completes Interim Sample Size Analysis of COVAMID Trial
01 Aug 2022 //
GLOBENEWSWIRE
Altamira Tx’s Delivery Platform with siRNA Shown to be Effective Treatment
28 Jul 2022 //
GLOBENEWSWIRE
Altamira to Develop Novel Generation of Rheumatoid Arthritis Therapeutics
25 Jul 2022 //
GLOBENEWSWIRE
Altamira`s SemaPhore Platform is Effective in Intracellular mRNA Delivery
19 Jul 2022 //
GLOBENEWSWIRE
Altamira Therapeutic’s RNA Delivery Platform Shown to be an Effective Treatment
12 Jul 2022 //
ACCESSWIRE
Altamira Tx Receives FDA 510(k) Clearance for Bentrio to Treat Allergic Rhinitis
27 Jun 2022 //
ACCESSWIRE
